# A Brief Intervention for Cannabis Use > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/brief-interventions-cannabis-use-disorder-clinical-trial/ > **Published:** 2026-05-08T15:05:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:15:53-04:00 > **Clinical Summary:** New clinical trial tests brief interventions for cannabis use disorder in young adults, using biological markers to validate treatment outcomes. --- CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🧪 [Clinical Trial](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) Watch  |  CED Clinic Trial ID NCT06395389 Status Recruiting Condition [Cannabis Use Disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) Intervention Health Education (HealthEdu) Why This Matters [Cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder affects nearly 3 million emerging adults annually, yet evidence-based brief interventions remain limited for this critical developmental period. This trial addresses a significant gap in scalable, age-appropriate [cannabis treatment options](https://cedclinic.com/medical-cannabis-evaluation-right-for-you/) when early intervention could prevent progression to severe dependency. Clinical Summary This randomized controlled trial compares two brief interventions for potentially problematic [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in emerging adults aged 18-25. The study employs a rigorous design with two 40-50 minute sessions separated by one week, followed by assessments at post-intervention, 1-month, and 3-month intervals. Biological validation through salivary THC and CBD testing accompanies self-report measures at all four timepoints. The trial is currently recruiting participants for this Phase II behavioral intervention study. Dr. Caplan’s Take “If positive, this trial could provide me with evidence-based brief intervention protocols specifically validated for emerging adults with cannabis use concerns. Having structured, time-limited interventions with demonstrated efficacy would significantly enhance my ability to offer targeted early intervention before patterns become entrenched.” Clinical Perspective 🧠 Emerging adults considering participation should understand this represents cutting-edge research in cannabis intervention during a critical developmental window. Clinicians should monitor this trial’s outcomes as brief interventions could become standard-of-care for early cannabis use concerns, particularly given the biological validation component that strengthens outcome reliability. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20A%20Brief%20Intervention%20for%20Cannabis%20Use%20%40drcaplan&url=https%3A//clinicaltrials.gov/study/NCT06395389)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//clinicaltrials.gov/study/NCT06395389)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20A%20Brief%20Intervention%20for%20Cannabis%20Use%20--%20via%20%40drcaplan.bsky.social%20https%3A//clinicaltrials.gov/study/NCT06395389)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://clinicaltrials.gov/study/NCT06395389](https://clinicaltrials.gov/study/NCT06395389) Table of Contents - [FAQ](#FAQ)[Who is this brief cannabis intervention trial designed for?](#Who_is_this_brief_cannabis_intervention_trial_designed_for) - [How much time does taking part in this trial involve?](#How_much_time_does_taking_part_in_this_trial_involve) - [How will researchers verify participants’ reported cannabis use?](#How_will_researchers_verify_participants8217_reported_cannabis_use) - [Is this cannabis intervention trial still enrolling, and are results available?](#Is_this_cannabis_intervention_trial_still_enrolling_and_are_results_available) - [Related](#Related) ## FAQ ### Who is this brief cannabis intervention trial designed for? The trial is designed for emerging adults aged 18 to 25 with potentially problematic cannabis use, and the condition listed is [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/). It is a randomized controlled trial that compares two brief interventions, one of which is listed as Health Education (HealthEdu). ### How much time does taking part in this trial involve? Participants attend two sessions of 40 to 50 minutes each, separated by one week. The sessions are followed by assessments right after the intervention, at one month, and at three months, so participation continues for up to three months after the intervention. ### How will researchers verify participants’ reported cannabis use? The trial pairs self-report measures with biological testing. Saliva is tested for THC and CBD at all four assessment timepoints, providing an objective check alongside what participants report about their own cannabis use. The article describes the design as rigorous, and this biological validation is part of it. ### Is this cannabis intervention trial still enrolling, and are results available? The trial, registered as NCT06395389, is listed as currently recruiting participants. It is a Phase II behavioral intervention study, and the article does not report any results, so it is not yet known whether either brief intervention reduces problematic cannabis use in emerging adults. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).